Hepatitis B virus e antigen production is dependent upon covalently closed circular (ccc) DNA in HepAD38 cell cultures and may serve as a cccDNA surrogate in antiviral screening assays

Antiviral Research

Volumn 72, Issue 2, 2006, Pages 116-124

  Zhou, Tianlun ^a   Guo, Haitao ^b   Guo, Ju Tao ^b   Cuconati, Andrea ^a   Mehta, Anand ^b   Block, Timothy M ^b  

^a HEPATITIS B FOUNDATION   (United States)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Antiviral assay; cccDNA; Hepatitis B virus

Indexed keywords

CIRCULAR DNA; COVALENTLY CLOSED CIRCULAR DNA; GENE PRODUCT; HEPATITIS E ANTIGEN; MESSENGER RNA; UNCLASSIFIED DRUG; VIRUS DNA;

ANTIGEN EXPRESSION; ANTIVIRAL ACTIVITY; ARTICLE; CHRONIC HEPATITIS; CONTROLLED STUDY; DRUG SCREENING; DRUG TARGETING; HEPATITIS B; HEPATITIS B VIRUS; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; VIRUS INFECTION; VIRUS LOAD;

5' UNTRANSLATED REGIONS; CELL LINE, TUMOR; DNA, CIRCULAR; DRUG EVALUATION, PRECLINICAL; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HUMANS; RNA, MESSENGER; RNA, VIRAL; VIRUS REPLICATION;

HEPATITIS B VIRUS;

EID: 33748305988     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.antiviral.2006.05.006     Document Type: Article

References (43)

1. Acs G., Sells M.A., Purcell R.H., Price P., Engle R., Shapiro M., and Popper H. Hepatitis B virus produced by transfected Hep G2 cells causes hepatitis in chimpanzees. Proc. Natl. Acad. Sci. USA 84 (1987) 4641-4644
2. Addison W.R., Walters K.A., Wong W.W., Wilson J.S., Madej D., Jewell L.D., and Tyrrell D.L. Half-life of the duck hepatitis B virus covalently closed circular DNA pool in vivo following inhibition of viral replication. J. Virol. 76 12 (2002) 6356-6363
3. Anderson A.L., Banks K.E., Pontoglio M., Yaniv M., and McLachlan A. Alpha/beta interferon differentially modulates the clearance of cytoplasmic encapsidated replication intermediates and nuclear covalently closed circular hepatitis B virus (HBV) DNA from the livers of hepatocyte nuclear factor 1alpha-null HBV transgenic mice. J. Virol. 79 17 (2005) 11045-11052
4. Chou Y.C., Jeng K.S., Chen M.L., Liu H.H., Liu T.L., Chen Y.L., Liu Y.C., Hu C.P., and Chang C. Evaluation of transcriptional efficiency of hepatitis B virus covalently closed circular DNA by reverse transcription-PCR combined with the restriction enzyme digestion method. J. Virol. 79 3 (2005) 1813-1823
5. Delaney W.E.t., Miller T.G., and Isom H.C. Use of the hepatitis B virus recombinant baculovirus-HepG2 system to study the effects of (-)-beta-2′,3′-dideoxy-3′-thiacytidine on replication of hepatitis B virus and accumulation of covalently closed circular DNA. Antimicrob. Agents Chemother. 43 8 (1999) 2017-2026
6. Fu L., and Cheng Y.C. Characterization of novel human hepatoma cell lines with stable hepatitis B virus secretion for evaluating new compounds against lamivudine- and penciclovir-resistant virus. Antimicrob. Agents Chemother. 44 12 (2000) 3402-3407
7. Ganem D., and Varmus H.E. The molecular biology of the hepatitis B viruses. Ann. Rev. Biochem. 56 (1987) 651-693
8. Guo H., Mason W.S., Aldrich C.E., Saputelli J.R., Miller D.S., Jilbert A.R., and Newbold J.E. Identification and characterization of avihepadnaviruses isolated from exotic anseriformes maintained in captivity. J. Virol. 79 5 (2005) 2729-2742
9. Guo J.-T., Zhou H., Liu C., Aldrich C., Saputelli J., Whitaker T., Barrasa M.I., Mason W.S., and Seeger C. Apoptosis and regeneration of hepatocytes during recovery from transient hepadnavirus infection. J. Virol. 74 (2000) 1495-1505
10. Guo J.T., Pryce M., Wang X., Barrasa M.I., Hu J., and Seeger C. Conditional replication of duck hepatitis B virus in hepatoma cells. J. Virol. 77 3 (2003) 1885-1893
11. Hirt B. Selective extraction of polyoma DNA from infected mouse cell cultures. J. Mol. Biol. 26 2 (1967) 365-369
12. Janssen H.L., van Zonneveld M., Senturk H., Zeuzem S., Akarca U.S., Cakaloglu Y., Simon C., So T.M., Gerken G., de Man R.A., Niesters H.G., Zondervan P., Hansen B., and Schalm S.W. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 365 9454 (2005) 123-129
13. Kock J., and Schlicht H.J. Analysis of the earliest steps of hepadnavirus replication: genome repair after infectious entry into hepatocytes does not depend on viral polymerase activity. J. Virol. 67 8 (1993) 4867-4874
14. Ladner S.K., Otto M.J., Barker C.S., Zaifert K., Wang G.H., Guo J.T., Seeger C., and King R.W. Inducible expression of human hepatitis B virus (HBV) in stably transfected hepatoblastoma cells: a novel system for screening potential inhibitors of HBV replication. Antimicrob. Agents Chemother. 41 8 (1997) 1715-1720
15. Lai C.L., Rosmawati M., Lao J., Van Vlierberghe H., Anderson F.H., Thomas N., and Dehertogh D. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Gastroenterology 123 6 (2002) 1831-1838
16. Lau G.K., Piratvisuth T., Luo K.X., Marcellin P., Thongsawat S., Cooksley G., Gane E., Fried M.W., Chow W.C., Paik S.W., Chang W.Y., Berg T., Flisiak R., McCloud P., and Pluck N. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N. Engl. J. Med. 352 26 (2005) 2682-2695
17. Lee W.M. Hepatitis B virus infection. N. Engl. J. Med. 337 24 (1997) 1733-1745
18. Liaw Y.F., Leung N.W., Chang T.T., Guan R., Tai D.I., Ng K.Y., Chien R.N., Dent J., Roman L., Edmundson S., and Lai C.L. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 119 1 (2000) 172-180
19. Locarnini S. Molecular virology and the development of resistant mutants: implications for therapy. Semin. Liver Dis. 25 Suppl. 1 (2005) 9-19
20. Marcellin P., Chang T.T., Lim S.G., Tong M.J., Sievert W., Shiffman M.L., Jeffers L., Goodman Z., Wulfsohn M.S., Xiong S., Fry J., and Brosgart C.L. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N. Engl. J. Med. 348 9 (2003) 808-816
21. Maynard M., Parvaz P., Durantel S., Chevallier M., Chevallier P., Lot M., Trepo C., and Zoulim F. Sustained HBs seroconversion during lamivudine and adefovir dipivoxil combination therapy for lamivudine failure. J. Hepatol. 42 2 (2005) 279-281
22. McMahon B.J. Epidemiology and natural history of hepatitis B. Semin. Liver Dis. 25 Suppl. 1 (2005) 3-8
23. Moraleda G., Saputelli J., Aldrich C.E., Averett D., Condreay L., and Mason W.S. Lack of effect of antiviral therapy in nondividing hepatocyte cultures on the closed circular DNA of woodchuck hepatitis virus. J. Virol. 71 12 (1997) 9392-9399
24. Perrillo R.P. Current treatment of chronic hepatitis B: benefits and limitations. Semin. Liver Dis. 25 Suppl. 1 (2005) 20-28
25. Scaglioni P.P., Melegari M., and Wands J.R. Posttranscriptional regulation of hepatitis B virus replication by the precore protein. J. Virol. 71 1 (1997) 345-353
26. Seeger C., and Mason W.S. Hepatitis B virus biology. Microbiol. Mol. Biol. Rev. 64 1 (2000) 51-68
27. Shin M.S., Kang E.H., and Lee Y.I. A flavonoid from medicinal plants blocks hepatitis B virus-e antigen secretion in HBV-infected hepatocytes. Antiviral Res. 67 3 (2005) 163-168
28. Summers J., Jilbert A.R., Yang W., Aldrich C.E., Saputelli J., Litwin S., Toll E., and Mason W.S. Hepatocyte turnover during resolution of a transient hepadnaviral infection. Proc. Natl. Acad. Sci. USA 100 20 (2003) 11652-11659
29. Summers J., and Mason W.S. Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate. Cell 29 (1982) 403-415
30. Summers J., O'Connell A., and Millman I. Genome of hepatitis B virus: restriction enzyme cleavage and structure of DNA extracted from Dane particles. Proc. Natl. Acad. Sci. USA 72 (1975) 4597-4601
31. Summers J., Smith P.M., and Horwich A.L. Hepadnavirus envelope proteins regulate covalently closed circular DNA amplification. J. Virol. 64 6 (1990) 2819-2824
32. Sung J.J., Wong M.L., Bowden S., Liew C.T., Hui A.Y., Wong V.W., Leung N.W., Locarnini S., and Chan H.L. Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy. Gastroenterology 128 7 (2005) 1890-1897
33. Tencza M.G., and Newbold J.E. Heterogeneous response for a mammalian hepadnavirus infection to acyclovir: drug-arrested intermediates of minus-strand viral DNA synthesis are enveloped and secreted from infected cells as virion-like particles. J. Med. Virol. 51 1 (1997) 6-16
34. Tuttleman J.S., Pourcel C., and Summers J. Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells. Cell 47 (1986) 451-460
35. Wang G.H., and Seeger C. The reverse transcriptase of hepatitis B virus acts as a protein primer for viral DNA synthesis. Cell 71 4 (1992) 663-670
36. Wang G.H., and Seeger C. Novel mechanism for reverse transcription in hepatitis B viruses. J. Virol. 67 11 (1993) 6507-6512
37. Werle-Lapostolle B., Bowden S., Locarnini S., Wursthorn K., Petersen J., Lau G., Trepo C., Marcellin P., Goodman Z., Delaney W.E.t., Xiong S., Brosgart C.L., Chen S.S., Gibbs C.S., and Zoulim F. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 126 7 (2004) 1750-1758
38. Wieland S.F., Eustaquio A., Whitten-Bauer C., Boyd B., and Chisari F.V. Interferon prevents formation of replication-competent hepatitis B virus RNA-containing nucleocapsids. Proc. Natl. Acad. Sci. USA 102 28 (2005) 9913-9917
39. Wieland S.F., Spangenberg H.C., Thimme R., Purcell R.H., and Chisari F.V. Expansion and contraction of the hepatitis B virus transcriptional template in infected chimpanzees. Proc. Natl. Acad. Sci. USA 101 7 (2004) 2129-2134
40. Wu T.T., Coates L., Aldrich C.E., Summers J., and Mason W.S. In hepatocytes infected with duck hepatitis B virus, the template for viral RNA synthesis is amplified by an intracellular pathway. Virology 175 1 (1990) 255-261
41. Zhang Y.Y., Zhang B.H., Theele D., Litwin S., Toll E., and Summers J. Single-cell analysis of covalently closed circular DNA copy numbers in a hepadnavirus-infected liver. Proc. Natl. Acad. Sci. USA 100 21 (2003) 12372-12377
42. Zhu Y., Yamamoto T., Cullen J., Saputelli J., Aldrich C.E., Miller D.S., Litwin S., Furman P.A., Jilbert A.R., and Mason W.S. Kinetics of hepadnavirus loss from the liver during inhibition of viral DNA synthesis. J. Virol. 75 1 (2001) 311-322
43. Zoulim F. Antiviral therapy of chronic hepatitis B: can we clear the virus and prevent drug resistance?. Antivir. Chem. Chemother. 15 6 (2004) 299-305